1301706-55-7

Basic information

• Product Name: FMOC-LYS(PALMITOYL)-OH
• Synonyms: N-ALPHA-(9-FLUORENYLMETHYLOXYCARBONYL)-N-EPSILON-PALMITOYL-L-LYSINE;N-ALPHA-FMOC-N-EPSILON-PALMITOYL-L-LYSINE;FMOC-L-LYS(PALM)-OH;FMOC-LYSINE(PALMITOYL)-OH;FMOC-LYS(PAL)-OH;FMOC-N-EPSILON-PALMITOYL-L-LYSINE;Palmitoyl lysine;Nα-Fmoc-Nε-Palmitoyl-D-Lysine≥ 99% (HPLC)
• CAS NO: 1301706-55-7
• Molecular Formula: C37H54N2O5
• Molecular Weight: 606.84
• Mol File: 1301706-55-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: -15°C
• CAS DataBase Reference: FMOC-LYS(PALMITOYL)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-LYS(PALMITOYL)-OH(1301706-55-7)
• EPA Substance Registry System: FMOC-LYS(PALMITOYL)-OH(1301706-55-7)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1301706-55-7(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

Uses

Amino acid-lipid conjugate for the solid phase synthesis of peptide-lipids. Lipidated peptides have been shown in some cases to lead to increased cellular permeability and metabolic stability.

Upstream product

• 57-10-3 1-hexadecylcarboxylic acid 
• 105047-45-8 Fmoc-Lys-OH 
• 139122-42-2 palmitic acid pentafluorophenyl ester 
• 14464-31-4 palmitic acid N-succinimide ester 
• 71989-26-9 Fmoc-Lys(tert-butoxycarbonyl) 

Relevant articles and documents

Palmitoyl derivatives of GpMBP epitopes: T-cell response and peptidases susceptibility

We report for the first time the immunoadjuvant effects of lipoconjugation of peptide antigens in an in vitro system by using CD4+ T-cells. The lipopeptides obtained by conjugating a palmitoyl moiety at the Nα-terminal of Gln74 or at

Co-liposomes comprising a lipidated multivalent RGD-peptide and a cationic gemini cholesterol induce selective gene transfection in αvβ3 and αvβ5 integrin receptor-rich cancer cells

The αvβ3 and αvβ5 integrins, transmembrane glycoprotein receptors, are over-expressed in numerous tumors and in endothelial cells that constitute tumor blood vessels. As this protein selectively binds to the Arg-Gly-Asp (RGD) sequence containing peptides, it is an attractive way to target tumors. Herein we have developed novel formulations for integrin mediated selective gene delivery. These formulations are composed of a novel palmitoylated tetrameric RGD containing scaffold (named RAFT-RGD), cationic gemini cholesterol (GL5) and a natural helper lipid 1,2-dioleoyl-l-α- glycero-3-phosphatidylethanolamine (DOPE). We have optimized a co-liposomal formulation to introduce the multivalent RGD-containing macromolecule in GL5: DOPE (GL5D) mixture to produce GL5D-RGD. We have unambiguously shown the selectivity of these formulations towards cancer cells that over express αvβ3 and αvβ5 integrins. Two reporter plasmids, pEGFP-C3 and PGL-3, were employed for the transfection experiments and it was shown that GL5D-RGD liposomes increased exclusively the transfection in αvβ3 and αvβ5-overexpressing HeLa cells. This journal is the Partner Organisations 2014.